A repurposing programme evaluating repurposing transdermal Estradiol (tE2) patches for the treatment of prostate cancer within the PATCH and STAMPEDE trials: Current results and adapting trial design

Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing hormone analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen and are associated with significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because of cardiovascular toxicity. Transdermal oestrogen (tE2) patches are an alternative ADT, supressing testosterone without the associated oestrogen-depletion toxicities (osteoporosis, hot flushes, metabolic abnormalities) and avoiding cardiovascular toxicity.

Source: Clinical Oncology - November 7, 2023 Category: Radiology Authors: Duncan C. Gilbert, Matthew Nankivell, Hannah Rush, Noel W. Clarke, Stephen Mangar, Abdullah Al-hasso, Stuart Rosen, Roger Kockelbergh, Subramaniam Kananga Sundaram, Sanjay Dixit, Marc Laniado, Neil McPhail, Ahmed Shaheen, Simon Brown, Joanna Gale, John De Tags: Original Article Source Type: research